In recent years, immune checkpoint inhibitors blocking programmed cell death 1 and its ligand (PD-1/PD-L1) and cytotoxic T-lymphocyte antigen-4 (CTLA-4) have shown promising preliminary results in various kinds of tumours. The gene discussed is PDCD1; the disease is neoplasm.